Hepatic brucelloma with initially negative antibodies: Diagnostic challenges in an endemic region Authors: Demetrios Kolokythas, Dimitra Katsani, Evangelos Zeis, Ilia Maria Pappa, Stamatina Terzi, Dimitra Tsili, Pantelis Vassiliu Published: 2026 ABSTRACT AbstractHepatic abscess secondary to Brucella infection is an exceptionally rare clinical entity, accounting for approximately 1.7% of patients with brucellosis. Since its first description in 1904, hepatic abscess is reported as a rare complication of chronic brucellosis with a limited number of cases presented in the literature. Brucellosis itself most often follows an indolent or subclinical course, typically manifesting with low-grade fever, weight loss, malaise, myalgias, and arthralgias. Here, we report the case of a 44-year-old farmer from a rural endemic region who was presented with persistent low-grade fever over a period of approximately 2.5 months, characterized by evening exacerbations, associated with fatigue, sweating, and significant weight loss (15–20 kg). Initial serological testing for Brucella antibodies was negative. Due to ongoing diagnostic uncertainty, the patient underwent extensive evaluation across multiple levels of care, including imaging, abscess aspiration, and comprehensive laboratory testing (including tumor markers, cultures, and PCR), without establishment of a definitive diagnosis. He was treated empirically for presumed intra-abdominal infection but showed no clinical improvement. Following further deterioration, repeat serological testing demonstrated seroconversion. In the context of epidemiological exposure and clinical evolution, a diagnosis of probable brucellar hepatic involvement was made. Targeted therapy was initiated, resulting in clinical improvement. This case highlights the diagnostic challenges of brucellosis with initially negative serology and underscores the importance of repeated testing and sustained clinical suspicion in endemic settings.Keywords: Brucella melitensis, Brucellosis, Hepatic brucelloma, Liver abscess, Calcified hepatic abscess, Zoonotic infections Introduction Brucellosis is the most widespread zoonotic infection worldwide, caused by intracellular Gram-negative coccobacilli of the genus Brucella. The pathogen primarily affects domestic and wild animals and is transmitted to humans through direct contact with infected animals, consumption of raw or unpasteurized dairy products, or inhalation of contaminated aerosols [1]. Although exceedingly uncommon, human-to-human transmission has been documented, including vertical, transfusion-related, and sexual routes. The clinical spectrum of brucellosis is broad, ranging from acute to subacute or chronic forms, and its prevalence is highest in endemic regions such as the Mediterranean basin, the Middle East, Mexico, and parts of the Indian subcontinent [2]. Occupational exposure places farmers, veterinarians, and animal breeders at particularly high risk [3]. The disease has the potential to involve virtually any organ system, including the hepatosplenic, musculoskeletal, genitourinary, lymphoreticular, and gastrointestinal systems. Hepatic involvement is reported in the vast majority of patients, typically presenting with hepatomegaly and mild to moderate elevations in liver enzymes [4]. Brucelloma, defined as a hepatic or splenic abscess caused by Brucella spp., represents a rare and challenging complication of the disease, typically arising during its chronic phase. It is most commonly located in the liver, less frequently in the spleen, and occasionally involves both organs. The reported prevalence of brucelloma is below 2% among patients with brucellosis, yet in some cases it may constitute the initial manifestation of previously undiagnosed acute infection [5]. We describe a case of hepatic brucelloma in which early diagnostic tests were inconclusive, underscoring the need for a high index of clinical suspicion in endemic regions when patients present with persistent, undulating evening fevers. Case presentation A 44-year-old male farmer, livestock worker, and animal skinner, previously fully functional and physically active in his daily work, presented to the emergency department of a rural health center in mid-July with complaints of cough, low-grade fever of approximately 12 h’ duration, malaise, anorexia, and vague mild abdominal discomfort. His past medical history was notable only for sarcoidosis diagnosed in 2022, which had remained clinically quiescent and asymptomatic until the present illness. He also had a history of gastroesophageal reflux disease and episodic low back pain/sciatica, but no known history of diabetes mellitus, chronic liver disease, malignancy, renal disease, or other major comorbidities. Initial physical examination did not reveal focal abnormalities from the respiratory, gastrointestinal, or other organ systems. The presentation consisted of low-grade fever of short duration, generalized malaise, mild arthralgia/myalgia, and mild cough, and was therefore initially interpreted as a nonspecific flu-like illness. However, during the following week, the fever persisted and evolved into a predominantly evening pattern, prompting further investigation. His occupational history was notable for daily contact with livestock, and he reported occasional direct involvement in vaccination of his flock against brucellosis. He stated that dairy products were prepared according to official safety standards, and no clear exposure through improperly processed dairy products was documented. He reported no recent travel or residence abroad and lived in an area endemic for brucellosis. Over the subsequent weeks, the patient developed progressive constitutional deterioration, including persistent evening fever, sweating during defervescence, worsening malaise, increasing weakness, and, later, substantial unintentional weight loss. At the time of initial assessment, significant weight loss and profuse night sweats had not yet become prominent features; these developed later during the course of the illness. Thoracic computed tomography (CT) was performed in view of the persistent fever and his history of sarcoidosis. Although the thoracic CT was unremarkable for pulmonary pathology, it incidentally revealed a 17-mm calcified hepatic lesion. Notably, review of prior imaging demonstrated that the same finding had been reported on a chest CT performed one year earlier. Given the persistence of abdominal pain, accompanied by anorexia, malaise, fatigue, and quotidian evening fevers with no improvement after the administration of antipyretics and with profuse sweating, a comprehensive laboratory and imaging evaluation was undertaken. Laboratory investigation included a complete blood cell count, electrolytes and liver enzyme function, blood cοagulation factors, markers of inflammation, virology testing and cancer markers. Laboratory testing revealed leukocytosis (16ꞏ100/μl) with neutrophilic predominance (80%), an elevated erythrocyte sedimentation rate (ESR, 35 mm), mildly increased γ-glutamyl transferase (74 U/L) while the rest of liver enzymes were normal, and markedly elevated ferritin levels (1ꞏ796 ng/ml) interpreted as a marker of acute inflammation. Bearing in mind the differential diagnosis of a hepatic lesion, a Wright agglutination test and serological assays for Brucella antibodies were tested and were negative at that time. Contrast-enhanced computed tomography (CT) of the abdomen demonstrated a large hypodense lesion measuring 7 × 5ꞏ5 cm in the peripheral aspect of the right hepatic lobe, extending towards and obscuring the hepatic capsule, with central calcification. Magnetic resonance imaging (MRI) confirmed the presence of a cystic lesion at the same location, measuring 8 × 6ꞏ9 × 6ꞏ3 cm, characterized by thickened walls and intralesional calcifications. Based on these findings, the patient was referred to the surgical department of the local hospital for further evaluation. At the surgical department of the local hospital, further evaluation was undertaken. Besides a complete blood count, hepatic biochemistry and electrolytes, testing was performed for cancer markers (CA19–9, AFP, CEA) and Widal and Wright testing as well as anti-echinococcal antibodies. Serological testing revealed elevated IgG and negative IgM antibodies for Brucella, while no biochemical or imaging evidence suggested malignancy or other active disease (negative antibodies for Salmonella and Echinococcus). A repeat abdominal CT, MRI, and MRCP were performed, to confirm the imaging findings, and the patient was subsequently discharged on empiric dual antimicrobial therapy consisting of cefixime and metronidazole, combined with methylprednisolone as an empiric treatment of hepatic abscess. The differential diagnosis at that time included hepatic abscess of either neoplastic origin or infectious etiology, such as Echinococcus spp. He was referred to a university hospital for further workup. There, the patient was re-tested for anti-echinococcal antibodies, anti- amoebic antibodies and anti-cysticercosis antibodies that all were negative. Also, a percutaneous liver puncture with aspiration of the lesion was performed; however, culture of the aspirated material yielded no microbial growth although it is unclear from the patients’ documentation which techniques for diagnosing Brucella were used. Fungal cultures were also negative. The negative cultures could be a result of ongoing antimicrobial administration and/or a low concentration of the infectious organism in the specimen. The patient was discharged with the recommendation to continue dual antibiotic therapy for 4–6 weeks. Within days of treatment, he was re-evaluated at the local health center, reporting persistent evening fevers, profuse sweating, malaise, worsening abdominal pain, and a sensation of fullness in the right upper quadrant. Additionally, he expressed significant concern regarding his health and reported difficulty continuing his farm work. Due to progressive clinical deterioration, the patient underwent repeated laboratory evaluation at a different external facility. Due to high clinical suspicion of an infection caused by Brucella, based on the patients epidemiological exposure history and imaging findings, and by suspecting a possible diagnostic laboratory error, serology was repeated. Results demonstrated a positive serological titer for Brucella melitensis (1:160) along with positive IgA and IgG antibody titers indicating a relapse of chronic Brucellosis. Hematological parameters revealed leukocytosis (12ꞏ400/μl) with associated lymphopenia, while inflammatory markers were significantly elevated (C-reactive protein 55ꞏ1 mg/L, ferritin >2ꞏ000 ng/ml). In light of these findings, the patient’s clinical status, and a review of the existing literature on similar cases, and even in the absence of a positive blood culture or tissue biopsy for Brucella, a decision was made to initiate triple anti-brucellar therapy. Treatment consisted of gentamicin administered for 21 days in combination with doxycycline and rifampicin, both prescribed for a total duration of three months. Two and a half months after his initial presentation and with two weeks of targeted antimicrobial therapy, the patient became afebrile, reported increased strength, gradually regained his appetite and was able to resume his daily activities and work. Approximately two and a half months after the initial abdominal CT, repeat imaging to check the treatment course and decide about the duration of therapy, demonstrated interval enlargement of the hepatic lesion, now measuring 13 × 7ꞏ5 × 10 cm. The radiological differential diagnosis at that time included parasitic abscess and neoplasm. Concurrent laboratory testing revealed a downward trend in IgA and IgG antibody titers for Brucella. Given the patient’s steady clinical improvement and resolution of symptoms following 21 days of intravenous gentamycin in combination with oral doxycycline and rifampicin, a consensus was reached to continue close monitoring with repeat serological testing and follow-up imaging at the completion of the prescribed treatment plan. Notably, the transient radiological worsening observed at this early stage of treatment may plausibly be attributed to “spillage” of aspirated abscess material following percutaneous drainage—without evidence of lateral abdominal wall infiltration—as suggested by the subsequent progressive improvement and eventual resolution of these findings on follow-up CT scans. Six months after the initial presentation, as part of the follow-up, repeat abdominal CT demonstrated marked improvement with partial reversal of hepatic damage and reduction of the abscess dimensions to 5 × 4ꞏ2 × 5ꞏ2 cm. Concurrent laboratory evaluation showed normalization of most parameters, with the exception of persistently elevated ferritin (652ꞏ3 ng/ml) and positive IgG antibodies, while IgA antibodies were not assessed. Based on these findings, the decision was made to continue antimicrobial therapy for an additional three months, with a plan for subsequent re-evaluation. After completing a total of six months of combination therapy, follow-up CT imaging revealed further reduction of the lesion (4 × 3ꞏ3 × 4ꞏ2 cm) with no new abnormalities. At that time, ferritin levels remained elevated (1ꞏ000 ng/ml) and both IgA and IgG antibodies were still positive. The therapy lasted for 6 months in total with remarkable clinical, laboratory and imaging improvement. At one-year follow-up, performed five months after the last abdominal CT and with the patient remaining off treatment during this interval, repeat imaging demonstrated further reduction of the hepatic abscess, now measuring 2ꞏ8 × 2ꞏ6 cm. Laboratory evaluation revealed persistently elevated ferritin levels (835ꞏ1 ng/ml) and positive IgG antibodies for Brucella, while IgA antibody titers were negative (Table 1). Clinically, the patient remained asymptomatic and had resumed his normal daily activities. Table 1Serology findings. Cutoff values: IgM < 20 U/ml, IgA < 20 U/ml, IgG < 30 U/ml, Wright reaction < 1:80, Brucella melitensis < 1:80, Brucella abortus < 1:80. N.T: not tested.TimeIgM (U/ml)IgA (U/ml)IgG (U/ml)Wright agglutinationBrucella melitensistiterBrucella abortustiterDay 1N.TN.TN.TNegativeNegativeN.TDay 20N.TN.TNegativeNegativeNegativeN.TDay 609.6068.2102N.TN.TN.TDay 120Under triple antibiotic therapyN.T20.680.5N.T1:1601:80Day 1802.7N.T112N.TNegativeNegativeDiscontinuation of treatmentOne year later4.0228.345.2N.TNegativeNegativeOne and a half year laterN.T13.3158N.TNegativeNegativeTwo years later5.22.890.9N.TNegativeNegative Serology findings. Cutoff values: IgM < 20 U/ml, IgA < 20 U/ml, IgG < 30 U/ml, Wright reaction < 1:80, Brucella melitensis < 1:80, Brucella abortus < 1:80. N.T: not tested. At two-year follow-up, thoracoabdominal CT imaging demonstrated further regression of the hepatic abscess, now measuring 2ꞏ4 × 2ꞏ3 cm. The lesion has shown a surprising regression compared to the initial size (5 ×6.9 ×6.3 cm) with presence of barely discernible septations and coarse calcifications, showing only minimal contrast enhancement after intravenous administration of contrast material. Laboratory studies were within normal limits, with negative IgA titers, with the exception of persistently elevated ferritin (792 ng/ml) and positive IgG antibodies for Brucella. Clinically, the patient remained in good health and entirely asymptomatic with no evidence of relapse. He was advised to be re-evaluated by a liver specialist of the surgical department of the university hospital to discuss local extraction of the remaining lesion and if needed, surgical intervention. Follow-up imaging demonstrated gradual regression of the hepatic lesion after initiation of targeted anti-brucellar therapy. These radiological findings paralleled the patient’s progressive clinical improvement, including resolution of fever and constitutional symptoms, together with reduction of inflammatory markers. An overview of his laboratory values since the patient was first evaluated at the local Health Center can be seen in Table 2 (Table 2). Nevertheless, residual calcifications and chronic structural abnormalities persisted on imaging despite clinical recovery, consistent with the known delayed radiological resolution of focal brucellosis. No clinical, laboratory or radiological evidence of a relapse was observed during follow-up. Contrast-enhanced abdominal CT scans showing the evolution of the hepatic lesion. a. (03.08.2023): initial CT at presentation demonstrating a hypodense lesion in the right hepatic lobe with peripheral wall thickening and central calcification. b. (16.07.2025): follow-up CT after prolonged antimicrobial therapy showing marked regression of the lesion, with reduction in size and improved definition of the hepatic parenchyma. Axial contrast-enhanced abdominal CT images of the hepatic lesion at diagnosis and follow-up. a. Initial axial CT demonstrating a hypodense lesion in the right hepatic lobe with thickened peripheral wall and central calcification. b. Follow-up axial CT after completion of antimicrobial therapy, showing near-complete resolution of the lesion, with only minimal residual changes and restored hepatic parenchymal architecture. Table 2Overview of laboratory findings throughout the treatment.Time pointWBC (K/μL)Neutrophils %Hb (g/dL)Platelets (K/μL)ESR (mm/h)CRP (mg/L)Ferritin (ng/ml)γ-GT (U/L)BrucellaserologyInterpretationInitial diagnostic phase(18 Aug 2023)16.180.014.1469355.0179674Wright negative; Brucella melitensis negative; anti-Echinococcus IgG negativeMarked inflammatory activation with neutrophilic leukocytosis, thrombocytosis, hyperferritinemia, and mild cholestatic disturbance; Brucella serology still negativePre-targeted therapy / diagnostic deterioration(3 Nov 2023)12.473.213.0435—55.1> 200062IgG 80.5 U/ml; IgA 20.6 U/ml; Wright/Brucella pattern compatible with positivity at evaluable titersPersistent systemic inflammation with serological conversion supporting brucellosisEarly response after targeted treatment(26 Jan 2024)7.158.016.4254—1.8652.334IgG 112.0 U/ml positive; IgM 2.7 U/ml negative; Wright/Brucella below evaluable titerClear hematologic and inflammatory improvement; ferritin still elevatedLate follow-up(15 Oct 2024)6.342.817.226440.9835.151IgG 158.0 U/ml positive; IgA 13.3 U/ml negative; Wright/Brucella below evaluable titerSustained clinical/laboratory remission with persistent IgG positivity and residual hyperferritinemiaTwo-year interval follow-up(8 Jul 2025)7.352.215.7253—2.2792.539IgG 90.9 U/ml positive; IgA 2.8 U/ml negative; IgM 5.2 U/ml negative; Wright/Brucella below evaluable titerStable long-term remission; no active inflammatory pattern; slow decline of ferritin and IgG persistence Overview of laboratory findings throughout the treatment. Discussion Brucellosis, also known as undulant fever, Malta fever, and Mediterranean fever is a zoonotic infection with protean and nonspecific clinical manifestations, capable of involving virtually any organ system. Among the Brucella species, Brucella melitensis, primarily transmitted from sheep and goats, exhibits the highest pathogenicity in humans. Less virulent species include Brucella abortus, Brucella suis, and Brucella canis [6]. The disease most commonly presents with an insidious onset of fever, malaise, and the characteristic night sweats often described as having a strong, peculiar “moldy” odor. The fever pattern is variable, ranging from intermittent spikes with rigors to relapsing, mild, or prolonged low-grade fever. Additional reported symptoms encompass weight loss, diffuse arthralgias, low back pain, headache, dizziness, anorexia, dyspepsia, abdominal discomfort, cough, and neuropsychiatric manifestations such as depression. Physical findings in brucellosis are highly variable and often nonspecific; hepatomegaly, splenomegaly, and lymphadenopathy may occasionally be observed, although hepatic or splenic involvement is usually asymptomatic [1]. Since its first description in 1904, approximately 60 cases of hepatic brucelloma have been reported in the literature, with nearly half occurring in patients of Mediterranean origin. Brucelloma represents a rare complication characterized by caseous necrosis of granulomatous tissue induced by persistent Brucella organisms within macrophages. It may mimic pyogenic abscesses, granulomatous diseases, parasitic infections or hepatic malignancy. Diagnosis can be challenging because of the nonspecific clinical manifestations and imaging findings that may overlap with infectious, inflammatory and neoplastic conditions. These lesions most frequently arise during the chronic phase of the disease, typically 6–12 months or more after initial infection, when the pathogen remains latent. In the present case, however, the hepatic brucelloma constituted the first clinical manifestation of previously undetected brucellosis, effectively bridging the acute presentation with features of the chronic stage. In the present case, the initial clinical approach to a patient with acute symptomatology and persistent fever focused on excluding common infectious diseases, malignancy, and potential exacerbation of his known sarcoidosis. The eventual diagnosis was achieved through a combination of laboratory and imaging modalities, although the first serological tests proved misleading [7]. Typically, laboratory abnormalities include neutrophilia, elevated ESR, and increased C-reactive protein, whereas liver function tests are often within normal limits, as was observed in our patient. Ferritin levels are usually elevated as ferritin serves as an acute phase reactant and in the case hepatic brucelloma, it can be elevated due to chronic granulomatous inflammation, macrophage activation, hepatic involvement and cytokine-driven iron sequestration. In our case, initial laboratory investigations showed elevated inflammatory markers together with an elevation in γ-gt which is typical for hepatic brucelloma. Serial laboratory testing showed persistent inflammatory activity despite nonspecific initial findings. Serological assays remain the cornerstone of diagnosis, with the serum agglutination test (SAT) and enzyme-linked immunosorbent assay (ELISA) being most widely employed. The Wright and Rose Bengal tests frequently yield positive results. False negative serological testing has been reported in cases of localized chronic brucellosis and may occur because of low antibody titers or delayed humoral response. Additional tools such as polymerase chain reaction (PCR) and blood cultures are also valuable in confirming the diagnosis, though in our case blood culture was not performed [8]. This can present as an important diagnostic limitation in our case since there was no direct evidence to confirm the diagnosis. In our case, besides serological testing for brucellosis, additional investigations were performed to exclude other infectious agents, neoplasms and granulomatous diseases including tuberculosis and echinococcal testing. Histopathological examination or biopsy may occasionally aid in diagnosis, but similar to our findings, they are frequently nondiagnostic. In our case, a hepatic abscess on imaging was one of the initial findings together with the patient symptoms, leading us to explore the differential diagnosis. Hepatic abscesses can be caused by a broad spectrum of etiologies including different pyogenic, parasitic, mycobacterial, fungal and zoonotic infections. Pyogenic liver abscesses are usually caused by enteric gram-negative bacilli, such as Klebsiella pneumoniae infection and Escherichia coli infection as well as anaerobic organisms and should be carefully distinguished from brucellar abscesses. In immunocompromised hosts, infections caused by Amebiasis, Tuberculosis and fungal infections should also be considered. In addition, infected hydatid cysts related to Echinococcus species can be considered when discussing the differential diagnosis. Finally, hepatic malignancies, either primary or metastatic can mimic radiologically infectious abscesses. Our patient, living in an endemic region and due to his occupational exposure combined with his ongoing fever, led us to include Brucella in the differential diagnosis and perform further testing. Imaging plays a pivotal role in defining the exact localization of the lesion, assessing potential complications, and contributing to the final diagnosis. Although radiological findings may be nonspecific, the presence of nodular or central calcifications within hepatic or splenic abscesses is considered highly suggestive, and when combined with positive serology can confirm the diagnosis of brucelloma. Central calcification, in particular, has been described as a relatively specific imaging sign of the disease. According to the literature, plain radiographs, ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI) have all been utilized in the diagnostic workup [9], [10]. Plain abdominal radiographs may reveal one or more calcific deposits in the hepatic area, while the most frequent ultrasonographic finding is a hypoechoic mass. In our case, CT was performed to further characterize the calcifications and internal architecture of the lesion. The CT demonstrated a hypodense lesion in the right hepatic lobe with a peripheral thickened wall and central calcification, consistent with descriptions in previously reported cases. MRI was subsequently performed for better assessment of the lesion composition, extent and the differential diagnosis considerations. In our case MRI provided less specific findings, characterizing the lesion as cystic with thickened walls and intralesional calcifications. Typically, however, MRI features of hepatic brucelloma include a heterogeneous hypointense lesion on T1-weighted images, a hyperintense region with surrounding hypointense tissue on T2-weighted sequences, and multiple fluid-containing locules with peripheral enhancement following intravenous gadolinium administration [11]. Liver biopsy specimens obtained under ultrasonographic guidance are frequently nonspecific, often demonstrating only foci of caseous necrosis or caseous-like areas surrounded by epithelioid granulomas. Such histopathological features are not pathognomonic and may also be encountered in other granulomatous diseases, including tuberculosis, yersiniosis, and tularemia caused by Francisella tularensis. In most reported cases of hepatic brucelloma, management requires a combination of antimicrobial therapy and surgical intervention [12]. First-line antimicrobial regimens typically include rifampicin in combination with doxycycline, while monotherapy is rarely advocated due to the high risk of relapse [13], [14]. A 2012 Cochrane review concluded that the regimen of doxycycline for six weeks combined with streptomycin for two weeks was more effective than doxycycline with rifampicin [15], [16], [17]. Therapeutic decisions are typically individualized according to lesion characteristics, chronicity, clinical severity, microbiological findings, and radiological evolution. Prolonged combination antimicrobial therapy is generally favored in focal disease because of the risk of relapse and incomplete eradication. The duration of antimicrobial therapy varies depending on the individual case and therapeutic response, with a median of two months, but ranging from six weeks to several months [18], [19]. Our patient initially was treated with the empiric treatment of cefixime and metronidazole. At the early couse of the disease, the nature of the hepatic lesion was uncertain so a pyogenic intra-abdominal infectious process could not be excluded. So, the aforementioned treatment was initiated to provide broad coverage for common enteric Gram-negative and anerobic pathogens. The administration of methylprednisolone was decided because of an evident marked inflammatory response with persistent constitutional symptoms (unresolving fever) and until the final diagnosis was made, when, it was discontinued. After the definitive diagnosis was made with positive serology, a triple regime was started with gentamycin, which is according to literature an alternative to streptomycin. This choice was made because of greater local availability of the drug (the patient lives in a small village) and also because the nursing staff of the local health case facility was more familiar with its use. The iv administration of gentamycin lasted 3 weeks because of the focal involvement and chronic brucelloma formation, which were considered manifestations of complicated brucellosis requiring prolonged combination therapy. The initial plan for the duration of treatment that we used in this patient was 3 months because of the presence of focal hepatic disease and the chronic radiological appearance of the lesion. Later on, and based on the clinical response and the laboratory and imaging findings of the patient, the duration of the treatment was extended to 6 months in total. Treatment response was assessed by the resolution of constitutional symptoms of the patient, gradual improvement of the inflammatory markers and liver function tests, and also by the gradual regression of the hepatic lesion on the follow-up imaging. Serial serological measurements demonstrated fluctuating antibody positivity during follow-up. However, these findings were interpreted cautiously, as serological titers in brucellosis may remain elevated despite adequate treatment and do not consistently correlate with disease activity, particularly in chronic focal forms of infection. In hepatic brucelloma, radiological improvement may occur more slowly than clinical and biochemical recovery. Residual calcifications or persistent focal lesions can remain detectable despite adequate treatment and absence of relapse. In selected patients, percutaneous abscess drainage combined with antibiotic therapy has been attempted, although this approach may be ineffective and often necessitates subsequent surgical management. Hepatic resection is generally reserved for cases with persistent symptoms or failure of medical therapy and less invasive interventions. Prevention of human brucellosis relies primarily on protective measures among occupationally exposed individuals, including the use of rubber gloves, boots, and face masks, as well as adherence to strict personal hygiene. At the community level, pasteurization of milk and other dairy products remains a highly effective measure for safeguarding consumers. Eradication of brucellosis from domestic animals, which has been successfully achieved in several countries, substantially reduces the human reservoir of infection. Vaccination of at-risk livestock further decreases the prevalence of infected animals and, consequently, the risk to humans. In addition, household members of an index case should undergo clinical evaluation, and serological testing may be warranted to exclude asymptomatic infection [20]. Long-term follow-up in patients with brucellosis is essential to ensure avoidance of re-exposure to the original source of infection and to verify adherence to the prescribed antimicrobial regimen, both of which are critical in preventing relapse. Relapses and remissions are well-documented, and in such cases prolonged triple therapy, extending for six months or more, may be required. Importantly, relapsing brucellosis must be distinguished from reinfection, as immunity conferred by an initial episode may be insufficient to prevent subsequent infections. Multiple reinfections have been reported, particularly among veterinarians and other individuals with continuous occupational exposure. Monitoring disease activity during follow-up includes repeat serology and imaging studies until clinical resolution is achieved and laboratory parameters normalize. Serological dynamics provide important insights into disease stage: IgM antibodies typically rise during the acute phase, followed by IgA and IgG elevations in the subacute phase, while IgM declines and becomes negative as the disease progresses into its chronic phase. In brucellosis, serological dynamics provide important insights into disease stage and therapeutic response. IgG antibodies typically rise two weeks after disease onset, peak at 6–8 weeks, and decline sharply after six months, usually disappearing within the first year. In cases of inadequate or incomplete therapy, IgG levels may persist and stabilize, reflecting chronic brucellosis. IgA antibodies usually decline during the subacute phase and become negative in the chronic stage. The clinical significance of anti-Brucella IgA remains unclear compared with IgM and IgG responses. Nevertheless, some studies suggest that IgA antibodies may persist in chronic, relapsing or localized forms of brucellosis and may occasionally provide supplementary information during follow-up [21]. In our patient, IgM antibodies were persistently negative from the beginning of the laboratory workup, suggesting that acute infection was unlikely. This finding is further supported by the presence of a hepatic lesion on abdominal CT predating the onset of clinical symptoms. During treatment, IgA antibodies gradually decreased and eventually became negative at the last follow-up, while IgG antibodies showed a biphasic course, reaching a nadir of 45 before rising again to 158 at the final testing. Considered together with the literature, these findings most likely reflect a relapse of chronic brucellosis. Nevertheless, it must be emphasized that serological testing has limited specificity and should always be interpreted in conjunction with clinical findings and other laboratory parameters. Early in the disease course or in relapse phase, typically during the first one or two weeks after symptom onset, that IgM and IgG antibodies may still be below detection thresholds. Also, there are cases where the patient has been already started on blunt antibiotic therapy and then antibody testing was performed, so antibody response can be blunted. Furthermore, some assays have low sensitivity, and different laboratories can have different cutoff values. In some cases, when the patient is immunosuppressed, reduced antibody production can delay or prevent seroconversion. In conclusion, heightened physician awareness and timely intervention are crucial, particularly in endemic areas. In such settings, hepatic brucelloma should be considered in the differential diagnosis of a hepatic mass, especially when central calcification is present. The integration of imaging findings with supportive serological testing can facilitate accurate diagnosis and guide the selection of appropriate therapeutic strategies. Conclusion Hepatic abscess due to Brucella infection is an exceptionally rare complication, with only a limited number of cases documented in the literature [22]. Clinicians should maintain a high index of suspicion for hepatic brucelloma, particularly in endemic regions and in patients with compatible occupational exposures [23], [24]. Thorough clinical assessment and detailed anamnesis remain fundamental for timely recognition. Importantly, strong clinical suspicion based on patient history and physical findings should guide the diagnostic process even when initial serological testing proves negative or inconclusive. While CT and MRI are invaluable in delineating hepatic lesions, their findings are nonspecific, underscoring the need for integration with repeated serology and, when appropriate, surgical diagnostic tests. In the present case, the diagnostic work-up, long-term follow-up, and overall management were conducted predominantly within the framework of primary health care, with only limited interventions at tertiary hospitals. This highlights the capacity of primary care in rural and resource-limited settings to not only initiate but also sustain the management of complex zoonotic infections. Management typically necessitates prolonged antimicrobial therapy, with treatment durations of at least three months, though individualized adjustment is frequently required [25], [26]. Preventive measures remain paramount: adherence to protective practices among at-risk individuals, avoidance of raw or unpasteurized dairy products, and control of brucellosis in livestock through vaccination are effective strategies to reduce transmission. Ultimately, this case underscores the crucial role of primary health care in early recognition, comprehensive management, and long-term monitoring of patients in isolated and underserved regions. Heightened awareness, early intervention, and sustained preventive efforts are essential to mitigate the burden of this challenging zoonotic disease. Authors contribution DKO, DK, and EZ contributed to the literature review, data collection, and interpretation. DKO was responsible for patient follow-up after treatment. DK drafted the manuscript. DKO critically revised and edited the final text. All authors read and approved the final version of the manuscript. CRediT authorship contribution statement Dimitra Katsani: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. Evangelos Zeis: Investigation, Data curation. Ilia Maria Pappa: Investigation, Data curation. Stamatina Terzi: Data curation. Demetrios Kolokythas: Supervision, Resources, Project administration, Conceptualization. Dimitra Tsili: Validation, Conceptualization. Pantelis Vassiliu: Investigation. Patient consent Written informed consent was obtained from the patient for publication of this case report and accompanying, images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request. Declaration of Generative AI and AI-assisted technologies in the writing process During the preparation of this work the authors used ChatGPT professional version in order to improve readability and language. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. References